|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-5-8
|
|
pubmed:abstractText |
The outcome of children with relapsed Wilms' tumor is poor, especially with poor-risk factors such as unfavorable histology, early recurrence, previous three-drug therapy, relapse not confined to lungs and abdominal relapse following abdominal radiotherapy. We report the overall response rate, progression-free survival and overall survival of 11 children with relapsed and poor-risk Wilms' tumor following ifosfamide/carboplatin/etoposide (ICE) chemotherapy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
460-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11996479-Adolescent,
pubmed-meshheading:11996479-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11996479-Carboplatin,
pubmed-meshheading:11996479-Child, Preschool,
pubmed-meshheading:11996479-Etoposide,
pubmed-meshheading:11996479-Female,
pubmed-meshheading:11996479-Gastrointestinal Diseases,
pubmed-meshheading:11996479-Hematologic Diseases,
pubmed-meshheading:11996479-Humans,
pubmed-meshheading:11996479-Ifosfamide,
pubmed-meshheading:11996479-Infant,
pubmed-meshheading:11996479-Infusions, Intravenous,
pubmed-meshheading:11996479-Kidney Neoplasms,
pubmed-meshheading:11996479-Male,
pubmed-meshheading:11996479-Neoplasm Recurrence, Local,
pubmed-meshheading:11996479-Remission Induction,
pubmed-meshheading:11996479-Survival Rate,
pubmed-meshheading:11996479-Treatment Outcome,
pubmed-meshheading:11996479-Wilms Tumor
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Ifosfamide, carboplatin and etoposide in children with poor-risk relapsed Wilms' tumor: a Children's Cancer Group report.
|
|
pubmed:affiliation |
Lombardi Cancer Center, Georgetown University, Washington, DC, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
